Understanding how T cells resist PD-1 signaling in cancer
Official title: Molecular mechanisms underlying T cell resistance to PD-1 signaling
Funded at Icahn School of Medicine at Mount Sinai · NIH-11097169 · Data updated 2026-11-12
This study is looking at how T cells can overcome signals that usually keep them from working too hard, which is important for fighting cancer, especially for patients who haven't had success with current treatments that block those signals.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $422,500 |
| NIH project number | 5R35GM150989-03 |
| Project ID | NIH-11097169 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who have not responded to PD-1 blocking therapies or those experiencing inflammatory side effects from such treatments.
✕Less likely to help
Patients with cancers that are not influenced by PD-1 signaling may not receive any benefit from this research.
What this research studies
This research investigates the molecular mechanisms that allow T cells to resist the inhibitory effects of PD-1 signaling, which is crucial for preventing excessive inflammation and tissue damage. By studying how PD-1 interacts with T cells, the research aims to uncover the complex signaling pathways involved in T cell activation and differentiation. The findings could lead to improved therapies that enhance T cell responses against cancer, particularly for patients who do not currently benefit from existing PD-1 blocking treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that enhance the immune response in patients who do not respond to current therapies.
How similar studies have gone: Previous research has shown promising results in understanding PD-1 signaling and its role in cancer treatment, indicating that this approach has the potential for significant advancements.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Tocheva, Anna S — Icahn School of Medicine at Mount Sinai
- Study coordinator: Tocheva, Anna S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.